- Construction and efficient assembly of silica-based ultrasmall nanoparticle with anti-Her2 targeting antibodies
- Targeted nanoparticles effectively localize to Her2 expressing tumors in vivo
- Nanoparticles show low liver accumulation and high tumor to background ratios in vivo
- Targeted nanoparticles have the potential for use in staging, risk stratification, treatment planning and development of next generation therapeutics.
Marcello Marelli, Senior Scientist Antibody Discovery and Protein Engineering, AstraZeneca